drugset / Trial / NCT05369832
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Timeline
- Start
- 2022-12-16
- Primary completion
- 2025-01-21
- Completion
- 2025-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ozanimod | Small molecule | — | — |